98 related articles for article (PubMed ID: 38519469)
1. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
2. BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review.
Zhang M; Li Y; Zhang Z; Zhang X; Wang W; Song X; Zhang D
Curr Drug Targets; 2023; 24(14):1079-1092. PubMed ID: 37846578
[TBL] [Abstract][Full Text] [Related]
3. BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3.
Reggiani F; Talarico G; Gobbi G; Sauta E; Torricelli F; Manicardi V; Zanetti E; Orecchioni S; Falvo P; Piana S; Lococo F; Paci M; Bertolini F; Ciarrocchi A; Sancisi V
Nat Commun; 2024 Mar; 15(1):2567. PubMed ID: 38519469
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
5. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
7. High level of BRD4 promotes non-small cell lung cancer progression.
Liao YF; Wu YB; Long X; Zhu SQ; Jin C; Xu JJ; Ding JY
Oncotarget; 2016 Feb; 7(8):9491-500. PubMed ID: 26840017
[TBL] [Abstract][Full Text] [Related]
8. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC.
Shi L; Xiong Y; Hu X; Wang Z; Xie C
Int J Med Sci; 2021; 18(14):3090-3096. PubMed ID: 34400879
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.
Guo H; Zhang J; Qin C; Yan H; Liu T; Hu H; Tang S; Tang S; Zhou H
Cells; 2022 Oct; 11(20):. PubMed ID: 36291069
[TBL] [Abstract][Full Text] [Related]
10. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
11. All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity.
Ramírez-Labrada A; Pesini C; Santiago L; Hidalgo S; Calvo-Pérez A; Oñate C; Andrés-Tovar A; Garzón-Tituaña M; Uranga-Murillo I; Arias MA; Galvez EM; Pardo J
Front Immunol; 2022; 13():896228. PubMed ID: 35651603
[TBL] [Abstract][Full Text] [Related]
12. A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2.
Vitale E; Sauta E; Gugnoni M; Torricelli F; Manicardi V; Ciarrocchi A
Cancer Commun (Lond); 2022 Sep; 42(9):892-896. PubMed ID: 35451571
[No Abstract] [Full Text] [Related]
13. OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.
Gugnoni M; Manzotti G; Vitale E; Sauta E; Torricelli F; Reggiani F; Pistoni M; Piana S; Ciarrocchi A
J Exp Clin Cancer Res; 2022 Mar; 41(1):108. PubMed ID: 35337349
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
Buckle I; Guillerey C
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
Zeng Y; Lv X; Du J
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
